Clin Mol Hepatol.
2024 Apr;30(2):284-286. 10.3350/cmh.2024.0108.
In response to: Steatotic liver disease-know your enemies
- Affiliations
-
- 1Larner College of Medicine at the University of Vermont, Burlington, VT, USA
- 2Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, CA, USA
- 3Department of Epidemiology and Population Health, Stanford University Medical Center, Palo Alto, CA, USA
- KMID: 2554439
- DOI: http://doi.org/10.3350/cmh.2024.0108
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- A new Korean nomenclature for steatotic liver disease: Nonalcoholic Fatty Liver Disease (NAFLD) Nomenclature Revision Consensus Task Force on behalf of the Korean Association for the Study of the Liver (KASL)
- Steatotic liver disease: Know your enemies
- Ursolic acid: A promising therapeutic agent for metabolic dysfunction-associated steatotic liver disease via inhibition of SPP1-induced Th17 cell differentiation: Editorial on “Ursolic acid targets secreted phosphoprotein 1 to regulate Th17 cells against metabolic dysfunction-associated steatotic liver disease”
- Waiting for the changes after the adoption of steatotic liver disease
- Similar respiratory function including chronic obstructive pulmonary disease between non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease
